P08.06 NFDI4Immuno: a federated fair infrastructure to accelerate data sharing in cancer immunotherapy
Background Cutaneous melanoma (CM) is the most aggressive form of skin cancer, with an increasing incidence in recent years.Immunotherapy is considered the most promising therapeutic option for late-stage CM.However, resistance occurs in 40-65% of the cases and 20-30% of responding patients develop secondary resistance, mainly due to the immunosuppression imposed by the tumor microenvironment.For this reason, it is essential to investigate the complex interactions between immune cells and tumors.Methods So far, most of the studies in this context have relied on in vivo models.However, these models present both scientific and ethical limitations.In our lab, we have established an in vitro CM skin model that fully recapitulates skin pathophysiology.Therefore, our objective is now to optimize an immune competent in vitro CM skin model to study the crosstalk between tumor cells and the immune system, and to investigate the mechanisms underlying immunotherapy response and resistance.For this, we developed an in vitro CM skin model composed by a dermis equivalent made with fibroblasts and the extracellular matrix they secrete, and an epidermis equivalent composed by CM cells and keratinocytes that stratify into all the layers of the epidermis.Once the model was fully established, we added to the medium PBMCs previously isolated from healthy donors.To determine the best conditions that allow the immune cells to infiltrate the skin equivalent and migrate toward the CM cells, we tested different immune/CM cell ratios (3:1; 10:1; 30:1) and different incubation times (2, 3 and 4 days).In parallel, as a control condition, we performed the same model but without immune cells.After fixation, the models have been processed for paraffin embedding (for histological analysis with haematoxylin and eosin staining (H&E)) and cryopreservation (for immunofluorescence microscopy analysis).Results It is possible to recognize by H&E staining the presence of small round cells in the dermis of the model to which PBMCs were added for 4 days at a 30:1 ratio of PBMCs/CM cells, consistent with the morphology of this type of cells.This observation suggests that there was infiltration of PBMCs into the CM skin model.However, since H&E staining is not sufficient to discriminate between PBMCs and the other cell types, we intend to perform immunofluorescence using an antibody that recognizes CD45, a marker that is specifically expressed by PBMCs. ConclusionThe results obtained are promising due to the presence in the dermis of small, rounded cells that are morphologically compatible with PBMCs, suggesting their infiltration in the model.However, immunofluorescence staining is essential to confirm the results.Once established, this model will provide a clinically relevant platform to identify predictive biomarkers of immunotherapy response and novel therapeutic strategies to overcome immunotherapy resistance in CM.P08.
Read more